UBS Group Downgrades PROCEPT BioRobotics (NASDAQ:PRCT) to Neutral

PROCEPT BioRobotics (NASDAQ:PRCT) was downgraded by UBS Group from a “buy” rating to a “neutral” rating in a note issued to investors on Tuesday, MarketBeat Ratings reports. They presently have a $20.00 target price on the stock. UBS Group’s price objective would suggest a potential upside of 13.06% from the stock’s previous close.

A number of other research analysts also recently issued reports on the company. Wall Street Zen upgraded PROCEPT BioRobotics from a “strong sell” rating to a “sell” rating in a research note on Saturday, April 25th. Piper Sandler restated an “overweight” rating and set a $35.00 target price (up from $28.00) on shares of PROCEPT BioRobotics in a research note on Thursday, April 30th. Evercore assumed coverage on shares of PROCEPT BioRobotics in a report on Wednesday, June 24th. They set an “outperform” rating and a $30.00 price target on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of PROCEPT BioRobotics in a research note on Friday, July 17th. Finally, Truist Financial restated a “hold” rating and set a $25.00 target price (down from $30.00) on shares of PROCEPT BioRobotics in a research note on Thursday, July 2nd. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, eight have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, PROCEPT BioRobotics presently has an average rating of “Hold” and an average target price of $33.45.

PROCEPT BioRobotics Price Performance

NASDAQ PRCT opened at $17.69 on Tuesday. The business’s fifty day moving average is $23.18 and its 200 day moving average is $25.57. PROCEPT BioRobotics has a fifty-two week low of $16.67 and a fifty-two week high of $56.87. The company has a debt-to-equity ratio of 0.15, a quick ratio of 5.51 and a current ratio of 6.73. The company has a market capitalization of $1.01 billion, a PE ratio of -9.72 and a beta of 0.87.

PROCEPT BioRobotics (NASDAQ:PRCT) last issued its quarterly earnings results on Wednesday, April 29th. The company reported ($0.56) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.01). PROCEPT BioRobotics had a negative return on equity of 27.70% and a negative net margin of 31.82%.The company had revenue of $83.13 million during the quarter, compared to analysts’ expectations of $80.52 million. During the same quarter in the previous year, the company earned ($0.45) EPS. The business’s quarterly revenue was up 20.1% compared to the same quarter last year. Sell-side analysts predict that PROCEPT BioRobotics will post -1.53 earnings per share for the current year.

Institutional Investors Weigh In On PROCEPT BioRobotics

A number of institutional investors have recently added to or reduced their stakes in PRCT. Advisory Services Network LLC raised its position in shares of PROCEPT BioRobotics by 1.3% during the second quarter. Advisory Services Network LLC now owns 20,109 shares of the company’s stock valued at $1,158,000 after buying an additional 250 shares during the last quarter. Osaic Holdings Inc. boosted its position in shares of PROCEPT BioRobotics by 20.3% during the second quarter. Osaic Holdings Inc. now owns 2,001 shares of the company’s stock worth $115,000 after acquiring an additional 337 shares during the last quarter. ProShare Advisors LLC grew its stake in PROCEPT BioRobotics by 4.7% during the fourth quarter. ProShare Advisors LLC now owns 9,726 shares of the company’s stock valued at $306,000 after acquiring an additional 438 shares in the last quarter. California State Teachers Retirement System grew its stake in PROCEPT BioRobotics by 1.4% during the second quarter. California State Teachers Retirement System now owns 49,446 shares of the company’s stock valued at $2,848,000 after acquiring an additional 693 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd increased its holdings in PROCEPT BioRobotics by 436.3% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 917 shares of the company’s stock valued at $29,000 after acquiring an additional 746 shares during the last quarter. 89.46% of the stock is owned by hedge funds and other institutional investors.

PROCEPT BioRobotics News Roundup

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Negative Sentiment: Several firms, including Robbins Geller, Kirby McInerney, Rosen Law Firm and others, said a securities-fraud class action has been filed on behalf of investors who purchased PRCT shares between February 28, 2024, and February 25, 2026. The allegations reportedly involve material misstatements or omissions concerning the company’s business and inventory issues. The claims have not been proven in court. Robbins Geller class-action announcement
• Negative Sentiment: Investors who suffered losses have until September 22, 2026, to seek appointment as lead plaintiff. Although this deadline is procedural and does not establish liability, the volume of nearly simultaneous law-firm announcements increases headline, litigation and potential financial-risk concerns for PRCT shareholders. Kirby McInerney investor alert
• Negative Sentiment: A Seeking Alpha analysis also highlighted a potential execution issue: PROCEPT may be placing robotic systems faster than it is filling them with procedures or utilization, which could delay revenue conversion and profitability. This is analyst commentary rather than a new company filing, but it adds to investor concerns following the company’s recent quarterly loss and continued negative margins. Seeking Alpha analysis

About PROCEPT BioRobotics

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.